Zanidatamab,Tislelizumab,Trastuzumab
zymeworks,beigene,novartis
tomorrow at #wcgic2022 we will review herizon-gea-01, our phase 3 study for her2-positive gastroesophageal adenocarcinoma (gea), in a poster presentation authored by josep tabernero, md. find details: 
We’re on a mission to bring patients home to their loved ones, disease free.